Intellia Therapeutics (NTLA) Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform
Go back to Intellia Therapeutics (NTLA) Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform| (NASDAQ: NTLA) | Delayed: 17.84 +0.28 (1.59%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.56 | 52 Week High | $30.40 | |||
| Open | $17.33 | 52 Week Low | $11.86 | |||
| Day High | $18.08 | P/E | N/A | |||
| Day Low | $16.17 | EPS | $0.00 | |||
| Volume | 3,845,197 | |||||
